See All Slides - tctmd.com

Slides

Presentation TCT 2012

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

REDUCE Trial Update

Presenter: John Rhodes

October 22, 2012

Presentation TCT 2012

New Left Bundle Branch Block Is an Independent Predictor of Mortality After TAVR

Presenter: Patrick Houthuizen

October 22, 2012

Presentation TCT 2012

Non-Left Main Bifurcation Stenting: Updated Meta-analysis of Simple vs. Complex Techniques

Presenter: Somjot Brar

October 22, 2012

Presentation TCT 2012

The “Heart Team” Management Approach in Valvular Heart Disease: Components and Value Proposition - A Sustainable Model for the Future?

Presenter: A. Pieter Kappetein

October 22, 2012

Presentation TCT 2012

Tips and Tricks in LAA Deployment

Presenter: William Gray

October 22, 2012

Presentation TCT 2012

The Apica Left Ventricular Apical Access and Closure System: First-in-Human Use Experiences During TAVR

Presenter: Thomas Walther

October 22, 2012

Presentation TCT 2012

Intentional Risk “Drift” vs. Refinement in Risk Assessment: Data from SOURCE and Personal Experiences

Presenter: Martyn Thomas

October 22, 2012

Presentation TCT 2012

ASD Closure: The European Perspectives

Presenter: Horst Sievert

October 22, 2012

Presentation TCT 2012

Fiberoptic Cardioscopy for Use in Epicardial Injection of Cell Suspensions and Biomaterials

Presenter: Henricus Duckers

October 22, 2012

Advertisement

Slides

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

REDUCE Trial Update

New Left Bundle Branch Block Is an Independent Predictor of Mortality After TAVR

Non-Left Main Bifurcation Stenting: Updated Meta-analysis of Simple vs. Complex Techniques

The “Heart Team” Management Approach in Valvular Heart Disease: Components and Value Proposition - A Sustainable Model for the Future?

Tips and Tricks in LAA Deployment

The Apica Left Ventricular Apical Access and Closure System: First-in-Human Use Experiences During TAVR

Intentional Risk “Drift” vs. Refinement in Risk Assessment: Data from SOURCE and Personal Experiences

ASD Closure: The European Perspectives

Fiberoptic Cardioscopy for Use in Epicardial Injection of Cell Suspensions and Biomaterials

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content